Inventor · disambiguated record
Eliezer Masliah
Also filed as: MASLIAH ELIEZER
15 granted patents·12 pending applications·250 citations·filing 1997–2024
93Inventor score
Files withUNIV CALIFORNIA8SCHENK DALE B6PROTHENA BIOSCIENCES LTD5MASLIAH ELIEZER3JANSSEN ALZHEIMER IMMUNOTHERAP2
Top patents by PatentIndex Score
27 records- 0194US6175057B1Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathyUNIV CALIFORNIA·Filed 1997·Granted Jan 16, 2001·116 cites·23 claims
- 0293US8147833B2Prevention and treatment of synucleinopathic and amyloidogenic diseaseSCHENK DALE B·Filed 2008·Granted Apr 3, 2012·18 cites·4 claims
- 0392US7727957B2Treatment and delay of outset of Parkinson's diseaseJANSSEN ALZHEIMER IMMUNOTHERAP·Filed 2003·Granted Jun 1, 2010·44 cites·24 claims
- 0491US8506959B2Prevention and treatment of synucleinopathic and amyloidogenic diseaseSCHENK DALE B·Filed 2005·Granted Aug 13, 2013·13 cites·15 claims
- 0588US8450481B2Compounds for inhibiting protein aggregation, and methods for making and using themMASLIAH ELIEZER·Filed 2008·Granted May 28, 2013·8 cites·13 claims
- 0682US8846682B2Compound suitable for the treatment of synucleopathiesMASLIAH ELIEZER·Filed 2010·Granted Sep 30, 2014·8 cites·3 claims
- 0776US10947302B2Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using themUNIV CALIFORNIA·Filed 2017·Granted Mar 16, 2021·1 cites·18 claims
- 0875US7393994B2Transgenic mouse model for neurodegenerative diseasesUNIV CALIFORNIA·Filed 2001·Granted Jul 1, 2008·14 cites·20 claims
- 0973US8946165B2Compounds for reversing and inhibiting protein aggregation, and methods for making and using themMASLIAH ELIEZER·Filed 2009·Granted Feb 3, 2015·1 cites·16 claims
- 1073US8697082B2Prevention and treatment of synucleinopathic and amyloidogenic diseaseSCHENK DALE B·Filed 2004·Granted Apr 15, 2014·3 cites·15 claims
- 1170US2021032318A1Prevention and treatment of synucleinopathic and amyloidogenic diseasePROTHENA BIOSCIENCES LTD·Filed 2020·Application pending·0 cites
- 1268US2024254211A1Prevention and treatment of synucleinopathic and amyloidogenic diseasePROTHENA BIOSCIENCES LTD·Filed 2024·Application pending·0 cites
- 1366US2019300598A1Prevention and treatment of synucleinopathic and amyloidogenic diseasePROTHENA BIOSCIENCES LTD·Filed 2019·Application pending·0 cites
- 1462US2017349651A1Prevention and treatment of synucleinopathic and amyloidogenic diseasePROTHENA BIOSCIENCES LTD·Filed 2017·Application pending·0 cites
- 1561US7795495B2Transgenic mice for screening for inhibitors of protein aggregation and methods for making and using themUNIV CALIFORNIA·Filed 2007·Granted Sep 14, 2010·0 cites·6 claims
- 1660US6455757B1Transgenic mice expressing human APP and TGF-β demonstrate cerebrovascular amyloid depositsUNIV CALIFORNIA·Filed 1999·Granted Sep 24, 2002·21 cites·14 claims
- 1759US2012201842A1Prevention and treatment of synucleinopathic and amyloidogenic diseaseSCHENK DALE B·Filed 2012·Application pending·0 cites
- 1856US2016060331A1Prevention and treatment of synucleinopathic and amyloidogenic diseasePROTHENA BIOSCIENCES LTD·Filed 2015·Application pending·0 cites
- 1955US2012142902A1Prevention and Treatment of Synucleinopathic and Amyloidogenic DiseaseSCHENK DALE B·Filed 2011·Application pending·0 cites
- 2054US2004146521A1Prevention and treatment of synucleinopathic diseaseFiled 2003·Application pending·0 cites
- 2151US2014364610A1Compound suitable for the treatment of synucleopathiesNEUROPORE THERAPIES INC·Filed 2014·Application pending·0 cites
- 2250US2010031377A1Prevention and treatment of synucleinopathic and amyloidogenic diseaseELAN PHARM INC·Filed 2005·Application pending·0 cites
- 2347US7459601B2Human α synuclein expressing transgenic miceUNIV CALIFORNIA·Filed 2004·Granted Dec 2, 2008·0 cites·14 claims
- 2447US2016184416A1Prevention and Treatment of Synucleinopathic and Amyloidogenic DiseaseSCHENK DALE B·Filed 2015·Application pending·0 cites
- 2544US7276643B2Transgenic animals, cell lines derived therefrom, and methods for screening for anti-amyloidogenic agentsUNIV CALIFORNIA·Filed 2001·Granted Oct 2, 2007·0 cites·7 claims
- 2643US2011135660A1Prevention and treatment of synucleinopathic diseaseJANSSEN ALZHEIMER IMMUNOTHERAP·Filed 2010·Application pending·0 cites
- 2734US7226746B1Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative diseaseUNIV CALIFORNIA·Filed 1999·Granted Jun 5, 2007·3 cites·8 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →